Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1

Journal of Neuroimmunology

Volumn 195, Issue 1-2, 2008, Pages 151-156

  Niks, E H ^a   van Leeuwen, Y ^a   Leite, M I ^b   Dekker, F W ^a   Wintzen, A R ^a   Wirtz, P W ^c   Vincent, A ^b   van Tol, M J D ^a   Jol van der Zijde, C M ^a   Verschuuren, J J G M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c HAGA HOSPITAL   (Netherlands)

Author keywords

Antibodies; IgG4; Immunoglobulin isotypes; MuSK; Myasthenia gravis; Seronegative

Indexed keywords

ANTIBODY; AZATHIOPRINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; IMMUNOSUPPRESSIVE AGENT; PHOSPHOTRANSFERASE; PREDNISONE;

ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; CELL STRAIN HEK293; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; LINEAR REGRESSION ANALYSIS; MYASTHENIA GRAVIS; PLASMAPHERESIS; PRIORITY JOURNAL; SCORING SYSTEM; THYMECTOMY;

ADULT; ANTIBODY SPECIFICITY; ANTIGEN-ANTIBODY REACTIONS; AUTOANTIBODIES; CELL LINE, TRANSFORMED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOGLOBULIN G; LONGITUDINAL STUDIES; MALE; MYASTHENIA GRAVIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TRANSFECTION;

EID: 42049116542     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2008.01.013     Document Type: Article

References (17)

1. Aalberse R.C., van der Gaag R., and van Leeuwen J. Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J. Immunol. 130 (1983) 722-726
2. Bartoccioni E., Scuderi F., Minicuci G.M., Marino M., Ciaraffa F., and Evoli A. Anti-MuSK antibodies: Correlation with myasthenia gravis severity. Neurology 67 (2006) 505-507
3. Bhol K., Natarajan K., Nagarwalla N., Mohimen A., Aoki V., and Ahmed A.R. Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity. Proc. Natl. Acad. Sci. USA 92 (1995) 5239-5243
4. Brooke M.H. A Clinician's View of Neuromuscular Diseases. 2 ed (1986), Williams & Wilkins, Baltimore
5. DeChiara T.M., Bowen D.C., Valenzuela D.M., Simmons M.V., Poueymirou W.T., Thomas S., Kinetz E., Compton D.L., Rojas E., Park J.S., Smith C., DiStefano P.S., Glass D.J., Burden S.J., and Yancopoulos G.D. The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo. Cell 85 (1996) 501-512
6. Evoli A., Tonali P.A., Padua L., Monaco M.L., Scuderi F., Batocchi A.P., Marino M., and Bartoccioni E. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 126 (2003) 2304-2311
7. Futei Y., Amagai M., Ishii K., Kuroda-Kinoshita K., Ohya K., and Nishikawa T. Predominant IgG4 subclass in autoantibodies of pemphigus vulgaris and foliaceus. J. Dermatol. Sci. 26 (2001) 55-61
8. Hamano H., Kawa S., Horiuchi A., Unno H., Furuya N., Akamatsu T., Fukushima M., Nikaido T., Nakayama K., Usuda N., and Kiyosawa K. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N. Engl. J. Med. 344 (2001) 732-738
9. Hillman M., Törn C., Thorgeirsson H., and Landin-Olsson M. IgG4-subclass of glutamic acid decarboxylase antibody is more frequent in latent autoimmune diabetes in adults than in type 1 diabetes. Diabetologia 47 (2004) 1984-1989
10. Jaretzki A., Barohn R.J., Ernstoff R.M., Kaminski H.J., Keesey J.C., Penn A.S., and Sanders D.B. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55 (2000) 16-23
11. Jha S., Xu K., Maruta T., Oshima M., Mosier D.R., Atassi M.Z., and Hoch W. Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK). J. Neuroimmunol. 175 (2006) 107-117
12. Kong X.C., Barzaghi P., and Ruegg M.A. Inhibition of synapse assembly in mammalian muscle in vivo by RNA interference. EMBO Rep. 5 (2004) 183-188
13. Matsumoto T., Shima M., Fukuda K., Nogami K., Giddings J.C., Murakami T., Tanaka I., and Yoshioka A. Immunological characterization of factor VIII autoantibodies in patients with acquired hemophilia A in the presence or absence of underlying disease. Thromb. Res. 104 (2001) 381-388
14. McConville J., Farrugia M.E., Beeson D., Kishore U., Metcalfe R., Newsom-Davis J., and Vincent A. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann. Neurol. 55 (2004) 580-584
15. Oosterhuis H.J., Limburg P.C., Hummel-Tappel E., and The T.H. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 2. Clinical and serological follow-up of individual patients. J. Neurol. Sci. 58 (1983) 371-385
16. Selcen D., Fukuda T., Shen X.M., and Engel A.G. Are MuSK antibodies the primary cause of myasthenic symptoms?. Neurology 62 (2004) 1945-1950
17. Shiraishi H., Motomura M., Yoshimura T., Fukudome T., Fukuda T., Nakao Y., Tsujihata M., Vincent A., and Eguchi K. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann. Neurol. 57 (2005) 289-293